Chemcrux Enterprises Limited, a leading chemical manufacturing company, held its 29th Annual General Meeting (AGM) on September 24, 2025, passing several significant resolutions that could shape the company's future. The meeting, conducted through video conferencing, saw shareholders approve key measures including an employee stock option plan and an increase in authorized share capital.

Authorized Share Capital Increase

One of the most notable decisions was the approval to increase the company's authorized share capital. Shareholders gave the green light to raise the authorized share capital from Rs. 15.00 crore to Rs. 20.00 crore, divided into 2 crore equity shares of Rs. 10 each. This move provides Chemcrux Enterprises with additional flexibility for future capital raising activities and potential expansion plans.

Employee Stock Option Scheme

In a bid to attract and retain talent, the company introduced the Chemcrux Enterprises Employee Stock Option Scheme 2025 (ESOP 2025). The scheme, which received shareholder approval, authorizes the granting of 20 lakh stock options of Rs. 10 each to eligible employees. This includes employees of subsidiary companies, associate companies, joint ventures, and group companies, both in India and abroad. The Nomination and Remuneration Committee will administer the scheme, which involves the issuance of new equity shares rather than secondary market acquisitions.

Leadership Continuity

Shareholders also approved the continuation of three key directors' terms:

1. Girishkumar Shah will continue as Executive Chairman upon reaching the age of 70.
2. Sanjay Marathe's term as Managing Director was extended beyond his 70th birthday.
3. Bhanubhai Patel will remain as an Independent Director after turning 75.

These approvals ensure leadership stability and continuity in the company's management.

Other Key Resolutions

• The appointment of M/s. KSPS & Co. LLP as secretarial auditors for a five-year term from FY 2025-26 to FY 2029-30 was ratified.
• Shareholders re-appointed Sidhdhi Shah as a director, who was retiring by rotation.
• A final dividend of 10% (Re. 1 per equity share) for the financial year ended March 31, 2025, was declared.

Voting Results

The resolutions were passed with overwhelming majority, with most receiving over 99% votes in favor. The ESOP scheme, while approved, saw a slightly lower approval rate of 99.83% of votes cast.

The strong shareholder support for these resolutions indicates confidence in Chemcrux Enterprises' management and future strategies. The approved measures, particularly the ESOP scheme and increased share capital, position the company for potential growth and employee retention in the coming years.

Chemcrux Enterprises Limited, a prominent player in the bulk drug intermediates sector, has announced a series of significant corporate developments, including the resignation of its Chief Financial Officer (CFO).

CFO Resignation

Ramesh Kambariya, the company's CFO, has tendered his resignation, effective from the end of business hours on August 11, 2025. In his resignation letter, Kambariya cited his decision to pursue opportunities that offer better financial growth to meet personal goals. He expressed gratitude for the trust and support received during his tenure and committed to ensuring a smooth transition.

Financial Performance

The company's Board of Directors, in a meeting held on August 6, 2025, approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. The consolidated revenue from operations for Q1 FY2025-26 stood at ₹1,650.35 crore, showing a modest increase from ₹1,572.16 crore in the corresponding quarter of the previous year.

Key Corporate Actions

Several other important decisions were taken during the board meeting:

1. Employee Stock Option Scheme: The board approved the Chemcrux Enterprises Employee Stock Option Scheme 2025 ("ESOP 2025"), granting 20,00,000 options at ₹10 each to eligible employees.

2. Increase in Authorized Share Capital: The company plans to increase its authorized share capital from ₹15 crore to ₹20 crore, subject to shareholder approval.

3. Continuation of Directors: The board recommended the continuation of terms for three key directors upon reaching certain age milestones:

   • Girishkumar Shah as Whole Time Director and Executive Chairman (upon turning 70)
   • Sanjay Marathe as Managing Director (upon turning 70)
   • Bhanubhai Patel as Independent Director (upon turning 75)

4. Appointment of Secretarial Auditor: M/s. KSPS & Co. LLP has been recommended for appointment as the company's Secretarial Auditor for a five-year term starting FY 2025-26.

5. Annual General Meeting: The 29th Annual General Meeting is scheduled for September 24, 2025, to be held via video conferencing.

These developments signify Chemcrux Enterprises' focus on corporate governance, employee retention, and strategic growth. The company's ability to navigate these changes, particularly the CFO transition, will be crucial for its continued success in the competitive bulk drug intermediates market.

Financial Highlights

The company's financial performance shows a year-on-year increase in revenue, but a decrease in profitability, which may be attributed to various market factors and operational challenges.